Remission Clinical Trial
Official title:
Evaluation of the Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission
Few studies have been conducted on the quality of life of patients with stage IV melanoma.
Particularly, there is no data regarding the quality of life of patients with a
multimetastatic melanoma currently in remission.
Then, the main objective of this study is to evaluate the quality of life from a point of
view medico-psycho-social in patients with multimetastatic melanoma in remission for more
than 6 months.
The cutaneous melanoma, (9th rank of all cancers), was until recently neglected and poorly
known by the general public. The metastatic stages have dramatic rates of survival: 25% at 1
year and 2% at 5 years with a median of about 6.2 months. However, in the last ten years, the
treatment of metastatic forms has undergone a real revolution.
Its high metastatic potential for a very low initial tumor mass, gives evidence of a great
aggressiveness. The cutaneous melanoma is resistant to the main therapeutics (chemotherapy
and radiotherapy). Thanks to the emergence of immunotherapies and targeted therapies anti-RAF
(Rapidly Accelerated Fibrosarcoma) and anti-MEK (Mitogen-activated Extracellular) the
prognosis of patients with metastatic melanoma has considerably improved, increasing the
number of "long-term survivors".
However, these treatments can cause many adverse effects that can impact patients' quality of
life, despite a better tolerance compared to conventional chemotherapies. To our knowledge
there are no data regarding the quality of life of patients with metastatic melanoma
currently in remission.For this purpose, it is necessary to obtain solid data using validated
questionnaires. Thus, we have chosen to evaluate quality of life using specific
questionnaires to better understand patients' expectations, their difficulties, and then to
improve the relationship between the patient and the physician.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05116228 -
Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission
|
Phase 4 | |
| Recruiting |
NCT02140229 -
Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores?
|
N/A | |
| Active, not recruiting |
NCT03261206 -
Stopping Aminosalicylate Therapy in Inactive Crohn's Disease
|
Phase 4 | |
| Recruiting |
NCT05194943 -
Trends and Safety in Revisional Bariatric Surgery in Italy
|
||
| Completed |
NCT05358158 -
Chest dRain rEmoval intrAoperatively afTer thoracOscopic Wedge Resection
|
N/A | |
| Active, not recruiting |
NCT04916249 -
Testing an Herbal Pain Relief Patch to Reduce Pain in Cancer Survivors
|
Phase 2 | |
| Recruiting |
NCT03176875 -
Comparison of Partial and Exclusive Enteral Nutrition in the Treatment of Active Childhood-onset Crohn's Disease
|
N/A | |
| Recruiting |
NCT05735717 -
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
|
Phase 2 | |
| Recruiting |
NCT06452030 -
Changing Trunk Muscle Activation in Patients With Recurrent Low Back Pain in Remission
|
N/A | |
| Completed |
NCT05459987 -
Feasibility of Prediabetes Remission in Adults With Coronary Heart Disease
|
N/A | |
| Active, not recruiting |
NCT05433077 -
Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment
|
||
| Recruiting |
NCT05905003 -
AMP SCZ® Observational Study: PREDICT-DPACC
|
||
| Completed |
NCT06199817 -
The Effect Of Multiple Occupational Therapies On Functional Remission And Subjective Recovery For Schizophrenia
|
N/A | |
| Recruiting |
NCT03248180 -
Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States
|
N/A | |
| Not yet recruiting |
NCT06186999 -
Social and Demographic Determinants of Fatigue in Patients With Inflammatory Bowel Disease in Remission
|
||
| Completed |
NCT03831750 -
Assessing the Effectiveness of a Stress Reduction Intervention in Inflammatory Bowel Disease (IBD)
|
N/A | |
| Completed |
NCT03574948 -
5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores
|
Phase 2 | |
| Recruiting |
NCT03037190 -
Preservation of Residual Beta Cell Mass and Prevention of Celiac Disease in Children With Recent Onset Type 1 Diabetes
|
N/A | |
| Completed |
NCT03123640 -
Improving Drug Safety in Emergency Patients -a Randomized Controlled Trial
|
N/A | |
| Recruiting |
NCT05863936 -
Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis
|
Phase 3 |